The pharmaceutical industry must develop models of innovation that enable it to function effectively at scale in a stochastic environment, in which outcomes are inherently unpredictable and aggregating projects increases uncertainty.
Mega-Fund Shows Why Conventional Thinking Won’t Fix Pharma’s Innovation Crisis
